Posted on

MYND Life Sciences Inc. Announces RSU Grant

MYND Life Sciences Inc. Announces RSU Grant

VANCOUVER, BC, Sept. 29, 2021 /CNW/ – MYND Life Sciences Inc. (“MYND” or the “Company“), has granted an aggregate of 234,192 restricted share units (the “RSUs”) to officers and employees pursuant to the Company’s RSU plan.

The Company’s RSU and stock-based option plans are aimed to compensate and reward its directors, officers and employees for working towards the Company’s long-term objectives and in alignment with the shareholders’ best interest.

ABOUT MYND LIFE SCIENCES

MYND Life Science Inc. is a leading life sciences company focused on improving mental health. The Company has confirmed access to Health Canada psilocybin research and development through exemptions granted to its Chief Science Officer, Dr. Wilfred Jefferies. Four separate patents have been filed based on Dr. Jefferies’ very promising research and development that commenced in 2010 regarding the modulation of a specific gene using neuro agents such as psychedelics and other compounds. Research and development is currently being performed.

CONTACT INFORMATION
CEO Dr. Lyle Oberg
Email: IR@myndlifesciences.com 
Web: www.myndlifesciences.com

Forward-Looking Information
This press release contains “forward-looking information” and “forward-looking statements” within the meaning of applicable securities legislation. The forward-looking statements herein are made as of the date of this press release only, and the Company does not assume any obligation to update or revise them to reflect new information, estimates or opinions, future events, or results or otherwise, except as required by applicable law. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budgets”, “scheduled”, “estimates”, “forecasts”, “predicts”, “projects”, “intends”, “targets”, “aims”, “anticipates” or “believes” or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions “may”, “could”, “should”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information in this press release includes, long-term objectives, and management’s expectations regarding MYND’s growth. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of MYND to control or predict, that may cause MYND’s actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein, including, but not limited to, the risk factors set out under the heading “Risk Factors” in the Company’s final non-offering long form prospectus dated May 12, 2021 available for review on the Company’s profile at www.sedar.com. Such forward-looking information represents management’s best judgment based on information currently available. No forward-looking statement can be guaranteed, and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.

SOURCE Mynd Life Sciences Inc.

Posted on

MYND Life Sciences Announces Closing of Fully Subscribed $3 Million Convertible Debenture Unit Offering

MYND Life Sciences Announces Closing of Fully Subscribed $3 Million Convertible Debenture Unit Offering

VANCOUVER, BC, Sept. 9, 2021 /CNW/ – MYND Life Sciences Inc. (CSE: MYND) (OTC: MYNDF) (“MYND” or the “Company“) is pleased to announce, further to its news release of August 26, 2021, the closing of its non-brokered private placement offering (the “Offering“) under which it sold $3,000,000 aggregate principal amount of convertible debenture units (the “Debenture Units“) for gross proceeds of $2,700,000, representing an initial issue discount equal to 10% of the aggregate principal amount of the Debentures (as defined below).

Each Debenture Unit consists of (i) $1,000 principal amount of senior unsecured convertible debentures (the “Debentures“); (ii) common share purchase warrants (the “Warrants“) exercisable for 1,000 common shares in the Company (“Shares“).  The Debentures will mature on the date that is 24 months from the date of issuance (the “Maturity Date“) and shall bear interest at a rate of 5% per annum, payable on the Maturity Date.  The principal sum of the Debentures, or any portion thereof, may be converted into Shares of the Company at a conversion price of $0.75 per Share (the “Conversion Price”).  Each Warrant shall entitle the holder to acquire one additional common share (a “Warrant Share“) in the capital of the Company at a price of $1.00 per Warrant Share for a period of 24 months from the date of issuance.

The Company may force the conversion of all of the principal amount of the then outstanding Debentures at the Conversion Price prior to the Maturity Date, if the daily volume weighted average trading price (“VWAP“) of the Shares on the Canadian Securities Exchange (the “Exchange“) is greater than a 50% premium to the Conversion Price for any 15 trading days during any period of 30 consecutive trading days.

All Debentures and Warrants issued pursuant to the Offering, including any securities into which they may be converted or exercised, are subject to a statutory hold period of four months and one day from the date of issuance thereof.  The Company will use the proceeds of the Offering to advance its novel drug discovery platform, commercialize its diagnostic business unit and for general working capital.

For more information and to subscribe to the Company’s mailing list, please visit https://myndsciences.com/contact/

ABOUT MYND LIFE SCIENCES
MYND Life Sciences is a medicinal biotech and drug research and development company focused on neuro-pharmaceutical and novel psychedelic drug development, diagnostic approaches and vaccines. The Company is advancing medicinal substances through rigorous science and clinical trials.

CONTACT INFORMATION
Dr. Lyle Oberg, CEO
Email: ir@myndsciences.com 
Web: www.myndsciences.com

Forward-Looking Statements

This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of MYND to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release.  

Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

None of the securities issued in connection with the Offering will be registered under the United States Securities Act of 1933, as amended (the “1933 Act”), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.

Posted on

MYND Life Sciences Announces $3 Million Convertible Debenture Unit Offering

MYND Life Sciences Announces $3 Million Convertible Debenture Unit Offering

VANCOUVER, BC, Aug. 26, 2021 /PRNewswire/ – MYND Life Sciences Inc.  (CSE: MYND) (OTC: MYNDF) (“MYND” or the “Company“), is pleased to announce that it has entered into a binding term sheet in respect of a non-brokered private placement offering (the “Offering“) of debenture units (the “Debenture Units“) with a strategic institutional investor. The principal sum of the Debentures Units to be issued is up to $3,000,000.

“We are incredibly pleased to add a strategic institutional investor, who has been very active in deploying capital in novel psychedelic drug development companies, to participate in this round of financing, joining our broader investor base in advancing our novel drug discovery platform,” said MYND Life Sciences CEO Dr. Lyle Oberg. “This capital will enable the Company to accelerate the commercialization of its diagnostic biomarker division in addition to helping advance MYND’s various clinical trials which are expected to commence in Q4 of this year”.

Each Debenture Unit consists of (i) $1,000 principal amount of senior unsecured convertible debentures (the “Debentures“); and (ii) common share purchase warrants (the “Warrants“) exercisable for 1,000 common shares in the Company (“Shares“). The Debentures will mature on the date that is 24 months from the date of issuance (the “Maturity Date“) and shall bear interest at a rate of 5% per annum, payable on the Maturity Date. The principal sum of the Debentures, or any portion thereof, may be converted into Shares of the Company at a conversion price of $0.75 per Share (the “Conversion Price”). Each Warrant shall entitle the holder to acquire one additional common share (a “Warrant Share“) in the capital of the Company at a price of $1.00 per Warrant Share for a period of 24 months from the date of issuance. The Debentures will be issued at a discount equal to 10% of the aggregate principal amount of the Debentures.

The Company may force the conversion of all of the principal amount of the then outstanding Debentures at the Conversion Price prior to the Maturity Date, if the daily volume weighted average trading price (“VWAP“) of the Shares on the Canadian Securities Exchange (the “Exchange“) is greater than a 50% premium to the Conversion Price for any 15 trading days during any period of 30 consecutive trading days.

All Debentures and Warrants issued pursuant to the Offering, including any securities into which they may be converted or exercised, are subject to a statutory hold period of four months and one day from the date of issuance thereof. The Offering is subject to final acceptance by the Exchange. The Company will use the proceeds of the Offering to advance its novel drug discovery platform, commercialize its diagnostic business unit and for general working capital.

For more information and to subscribe to the Company’s mailing list, please visit https://myndsciences.com/contact/

ABOUT MYND LIFE SCIENCES

MYND Life Sciences is a medicinal biotech and drug research and development company focused on neuro-pharmaceutical and novel psychedelic drug development, diagnostic approaches and pharmaceuticals and vaccines. The Company is advancing medicinal substances through rigorous science and clinical trials.

Forward-Looking Statements

This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of MYND to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release.  

Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

None of the securities issued in connection with the Offering will be registered under the United States Securities Act of 1933, as amended (the “1933 Act”), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.

SOURCE Mynd Life Sciences Inc.

Posted on

MYND Life Sciences Announces DTC Eligibility

VANCOUVER, BC, Aug. 11, 2021 /PRNewswire/ – MYND Life Sciences Inc. (CSE: MYND) (OTC: MYNDF) (“MYND”) is a drug research and development company focused on novel psychedelic drug development, diagnostic approaches and pharmaceuticals and vaccines is pleased to announce that it is now eligible for Depository Trust Company (“DTC”) services in relation to the Company’s listing on the OTC. Through the OTC listing, investors from the United States may more easily trade MYNDF stock, in addition to MYND’s listing on the CSE “MYND” in Canada.

“We are excited to receive DTC eligibility, which not only provides the Company with access to a broader range of US-based investors but also provides additional opportunities for investors in the US to acquire MYND shares”, said MYND CEO, Dr. Lyle Oberg. “There are 300 million persons world-wide suffering from major depressive disorder and other related conditions who have not been well-served by the existing class of SSRIs to treat depression.  We are convinced we have the scientific capacity, the intellectual property and the right leadership to achieve the first substantive innovation in this drug class in a generation.”

DTC is a subsidiary of the Depository Trust and Clearing Corporation (DTCC), one of the world’s largest securities depositories that manage the electronic clearing and settlement of publicly-traded companies. MYND is now eligible to be electronically cleared and settled, which will streamline the process of trading, enhance liquidity, and provide direct access to investors in the United States OTC capital markets.

For more information and to subscribe to the Company’s mailing list, please visit https://myndsciences.com/contact/

ABOUT MYND LIFE SCIENCES

MYND Life Sciences is a medicinal biotech company focused on neuro-pharmaceutical drug development. The Company is advancing medicinal substances through rigorous science and clinical trials.

CONTACT INFORMATION
Dr. Lyle Oberg, CEO
Email: ir@myndsciences.com 
Web: www.myndsciences.com

Forward-Looking Statements

This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of MYND to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release.  

Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

SOURCE Mynd Life Sciences Inc.

Posted on

MYND Life Sciences Provides Corporate Update

VANCOUVER, BC, July 7, 2021 /PRNewswire/ – MYND Life Sciences Inc. (CSE: MYND) (“MYND”) is a drug research and development company focused on novel psychedelic drug development, diagnostic approaches, pharmaceuticals and vaccines, is pleased to provide a corporate update on its operations and progress on its strategic initiatives to the end of Q2 2021.

“A key difference between MYND and other psychedelic companies is that we are creating intellectual property by reducing to practice the bio-active forms of psychedelics to particular medical conditions. Applying psychedelic analogs to other medical conditions not currently being targeted for psychedelic analog therapies. Creating unique biomarkers for diagnosing and monitoring MDD, and responses to treatment of MDD. Finally, MYND is applying novel vaccine and immunotherapeutic approaches to diseases of the central nervous system. In this way, we plan to differentiate ourselves with a focus on building long-term value for our shareholders.” continued CEO Dr. Lyle Oberg.

Dr. Wilfred Jefferies, Chief Science Officer of MYND Life Sciences stated that “MYND’s investigational medical pipeline shows great promise, and we intend to use a three-pronged approach in the business:

  1. Objectively diagnose patients with depression and monitor improvement,
  2. Develop a solution to alleviate and reverse depression, and
  3. Create vaccines for diseases of the central nervous system.”

MYND is pursuing the development of a multifaceted suite of Central Nervous System (CNS) disorder treatment protocols and assessment tools that include:

    • Diagnostic biomarkers
    • Treatment of medical conditions with specific psilocybin and other psychedelic analogs
    • Vaccines and immunotherapeutics

“We accept that Psychedelics and Psilocybin benefit psychiatric illnesses such as Major Depressive Disorder (MDD) and other diseases. It is our goal and responsibility to move beyond this research and translate the findings and related technologies into mainstream medical practice,” said MYND CEO, Dr. Lyle Oberg. “Over the past 10 years, our Scientific Team has made great strides in identifying and examining the pathways involved in MDD and it is now time to use this knowledge to help the 300,000,000 + people suffering with psychiatric disease.”

Intellectual Property
MYND has expanded its Intellectual Property holdings with four separate patent applications, including:

  • A diagnostic biomarker with the potential to diagnose and monitor MDD and other diseases.
  • Modulation of key pathways in the treatment of MDD utilizing Psilocybin analogs.
  • Methods for regressing or delaying Alzheimer’s disease and related forms of dementia.
  • Modulation of the key pathways in the treatment of inflammatory diseases utilizing Psilocybin analogs.

Strategic Partnerships:

  1. University of British Columbia

    The Company announced the signing of a Collaborative Research Agreement (the “Agreement“) with the University of British Columbia (“UBC“) on February 2, 2021, focussing on Major Depressive Disorder, often referred to as depression. Results are to be expected as early as Q3-Q4 of 2021.

  2. SISCAPA Assay Technologies

    The Company’s agreement with SISCAPA Assay Technologies, announced June 1, 2021, will help enable MYND’s goal of more precisely diagnosing and monitoring the treatment regime for patients with Major Depressive Disorder (MDD) and other diseases. Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA) is a patented sample preparation methods platform for diagnostics that improves the performance of mass spectrometry (MS) for measurement of pre-selected protein targets. It is a method that will assist our research team with our proprietary panel of biomarkers aimed at diagnosing and monitoring Major Depressive Disorder. MYND aims to commercialize this panel by Q1 of 2022.

  3. Eyam Vaccines

    MYND entered into a Letter of Intent with Eyam Vaccines, Vancouver, British Columbia, to pursue the development of vaccines and immunotherapeutics that have the ability to prevent neurological disorders.

Clinical Trial Updates:

On May 15, 2021, MYND made the key hire of Iryna Saranchova, MD, PhD as its Chief Clinical Officer, whose role is to lead the implementation of the clinical trials from design through to evaluation. MYND has begun planning for clinical trials to start in Q1 of 2022, which includes several areas:

  1. Addressing the therapeutic impact of psilocybin and Psilocybin Analogs on depression and “Brain Fog” in patients with proven Covid 19.
  2. A trial to correlate the MYND Biomarker panel with the diagnosis and monitoring of MDD.
  3. Preparing and submission of a joint application with Monash University researchers, located in Melbourne, Australia, for an Adaptive Trial utilizing Psilocybin in the treatment of depression, sponsored by the Government of Australia. This trial has a submission deadline of July 15, 2021.

For more information and to subscribe to the Company’s mailing list, please visit https://myndsciences.com/contact/

ABOUT MYND LIFE SCIENCES

MYND Life Sciences is a medicinal biotech company focused on neuro-pharmaceutical drug development. The Company is advancing medicinal substances through rigorous science and clinical trials.

CONTACT INFORMATION
Dr. Lyle Oberg, CEO
Email: ir@myndsciences.com 
Web: www.myndsciences.com

Forward-Looking Statements

This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of MYND to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release.  

Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

SOURCE Mynd Life Sciences Inc.

Posted on

This Canadian psychedelic drug company is working on a vaccine for depression

“Diagnosing, preventing and treating diseases of the central nervous system is at the core of our focused corporate strategy.”

Vancouver-based MYND Life Sciences is exploring whether depression and other central nervous system disorders can be treated with novel psychedelic drugs, including psilocybin. In January, the company announced a collaborative research agreement with the University of British Columbia on major depressive disorder.“We have an opportunity to improve the wellness and quality of life of people suffering from depression, anxiety and addiction and this agreement helps set the foundation for the development of novel therapies utilizing psilocybin and other related compounds,” said Dr. Lyle Oberg, MYND’s chief executive officer.MYND is now one step closer to that goal after signing a licensing agreement with private vaccine developer Eyam.

The Letter of Intent, announced last month, gives MYND an exclusive license with respect to Eyam’s proprietary technologies for applications to central nervous system vaccines.This agreement with Eyam will allow MYND to access yet another cutting edge technology with the development of vaccines that have the ability to prevent neurological disorders such as major depressive disorder, by stopping the neuro-inflammatory process before it starts,” explains Dr. Oberg.MYND is working to develop a suite of central nervous system disorder treatment protocols, including diagnostic capacity with blood markers, treatment with specific psilocybin and other psychedelic analogs, and immunoprotection.

The company is also working on methods for treating or delaying Alzheimer’s disease and related forms of dementia.“Diagnosing, preventing and treating diseases of the central nervous system is at the core of our focused corporate strategy,” Dr. Oberg said last month. “Alzheimer’s disease affects millions of people around the globe and remains a catastrophic condition without a cure.”

Regina Leader-Post, July 3, 2021.

https://leaderpost.com/cannabis-news/psychedelics/this-canadian-psychedelic-drug-company-is-working-on-a-vaccine-for-depression

Posted on

Could a psychedelic vaccine prevent depression?

A New Vaccine Against Depression? | MYND Life Sciences

While many psychedelics companies are developing treatments for depression, MYND Life Sciences hopes to prevent depression from developing in the first place.

MYND recently signed a licensing agreement with Eyam, a private vaccine developer, to create a vaccine that would prevent neurological disorders including depression. The underlying theory is that depression is essentially neuro-inflammation, and psychedelics may have an anti-inflammatory effect that could prevent the neuro-inflammatory process.

PDF of article

Posted on

MYND Life Sciences Expands Intellectual Portfolio to Target Alzheimer’s disease and related forms of Dementia with Chemical Subclasses of Psilocybin Analogues

VANCOUVER, BC, June 23, 2021 /CNW/ – MYND Life Sciences Inc. (CSE: MYND) (“MYND“) a drug research and development company focused on novel psychedelic drug development, diagnostic approaches and pharmaceuticals, is pleased to announce it has expanded its intellectual property portfolio for diseases of the central nervous system, including methods for treating or delaying Alzheimer’s disease and related forms of dementia.

MYND’s research team has shown significant progress in advancing its proprietary technologies that may impact central nervous system diseases including Alzheimer’s disease and other forms of dementia by possibly delaying or in some instances potentially reversing the progress of these forms of diseases. MYND has bolstered its novel drug discovery pipeline by commencing preclinical testing of chemical subclasses of psilocybin analogues with the goal to enter clinical trials to treat Alzheimer’s disease and other related forms of dementia.

“Our preclinical research is uncovering new therapeutic approaches and we plan to exhaustively explore these new leads for treating Alzheimer’s disease and other dementias,” stated Dr. Wilf Jefferies, MYND’s Chief Science Officer.

The World Health Organization estimates that between 44 and 50 million people worldwide are suffering from Alzheimer’s disease or related forms of dementia. That includes approximately six million Americans and nearly one million Canadians suffering from dementias.

“Diagnosing, preventing and treating diseases of the central nervous system is at the core of our focused corporate strategy,” said Dr. Lyle Oberg, CEO of MYND Life Sciences. “Alzheimer’s disease affects millions of people around the globe and remains a catastrophic condition without a cure. MYND’s intellectual property holdings have recently been expanded to address unmet needs in treating Alzheimer’s disease that may create significant value for MYND shareholders.”

For more information and to subscribe to the Company’s mailing list, please visit https://myndsciences.com/contact/

ABOUT MYND LIFE SCIENCES

MYND Life Sciences is a medicine biotech company focused on neuro-pharmaceutical drug development. The Company is advancing medicinal substances through rigorous science and clinical trials.

Forward-Looking Statements

This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of MYND to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release.  

Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

SOURCE Mynd Life Sciences Inc.

For further information: CONTACT INFORMATION: Dr. Lyle Oberg, CEO, Email: ir@myndsciences.com, Web: www.myndsciences.com